From the Holland Hospital, Holland, MI.
Astellas Pharma, Inc., Northbrook, IL.
Menopause. 2024 Sep 1;31(9):769-780. doi: 10.1097/GME.0000000000002399.
To assess treatment satisfaction, unmet treatment needs, and new vasomotor symptom (VMS) treatment expectations among women with moderate to severe VMS and physicians treating women with VMS.
This noninterventional, nonrandomized survey included qualitative interviews and quantitative surveys of women and physicians in the US. Participating women had moderate to severe VMS in the past year and received ≥1 hormone therapy (HT), non-HT, or over-the-counter (OTC) treatment for VMS in the past 3 months. Participating physicians were obstetrician-gynecologists (OB-GYNs) and primary care physicians (PCPs) who treated ≥15 women with VMS in the past 3 months. Two online survey questionnaires were developed using insights from literature, qualitative interviews, and clinical experts. Menopause Symptoms Treatment Satisfaction Questionnaire (MS-TSQ) measured treatment satisfaction. Results were summarized descriptively.
Questionnaires were completed by 401 women with VMS and 207 physicians treating VMS. Among women, mean total MS-TSQ score ranges were 62.8-67.3 for HT, 59.8-69.7 for non-HT, and 58.0-64.9 for OTC treatments. Among physicians, mean total MS-TSQ scores were considerably higher for HT than for non-HT and OTC treatments (HT: 73.4-75.6; non-HT: 55.6-62.1; OTC: 49.2-54.7). Women reported "lack of effectiveness" (41.2%), and physicians reported "long-term safety concerns" (56.5%) as main features that do not meet their current treatment expectations. The majority of women and physicians would consider trying a new non-HT treatment for VMS (75.8 and 75.9%, respectively).
Treatment satisfaction and new treatment expectations were similar but with some differences between women and physicians; the need for additional treatments for VMS was identified.
评估有中重度血管舒缩症状（VMS）的女性患者及其治疗医生的治疗满意度、未满足的治疗需求，以及对 VMS 新治疗方案的期望。
本项非干预性、非随机调查包括对美国女性患者和医生的定性访谈和定量调查。参与研究的女性患者过去 1 年中有中重度 VMS，且过去 3 个月内接受过≥1 种激素治疗（HT）、非-HT 或非处方（OTC）药物治疗 VMS。参与研究的医生为妇产科医生（OB-GYN）和初级保健医生（PCP），过去 3 个月内治疗过≥15 例 VMS 患者。根据文献、定性访谈和临床专家的意见，开发了 2 个在线调查问卷。采用绝经症状治疗满意度问卷（MS-TSQ）评估治疗满意度。结果以描述性统计进行总结。
共完成了 401 例 VMS 女性患者和 207 例治疗 VMS 的医生的调查问卷。女性患者的 HT、非-HT 和 OTC 治疗的总 MS-TSQ 评分范围分别为 62.8-67.3、59.8-69.7 和 58.0-64.9。医生的 HT、非-HT 和 OTC 治疗的总 MS-TSQ 评分分别显著高于非-HT 和 OTC 治疗（HT：73.4-75.6；非-HT：55.6-62.1；OTC：49.2-54.7）。女性患者报告“缺乏疗效”（41.2%）和医生报告“长期安全性担忧”（56.5%）是目前未满足的治疗需求的主要特征。大多数女性患者和医生都愿意考虑尝试治疗 VMS 的新非-HT 治疗方案（分别为 75.8%和 75.9%）。
女性患者和医生的治疗满意度和新治疗期望相似，但也存在一些差异；确定了 VMS 额外治疗的需求。
